Paola Piccini

Paola Piccini

Auto-generated profile, based on publicly available information

Paola Piccini

Centre for Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2010 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MPMarios Politis
Marios Politis
KWKit Wu
Kit Wu
SMSophie Molloy
Sophie Molloy
PBPeter G. Bain
Peter G. Bain
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
PPPaola Piccini
Paola Piccini

1 December 1999 in Nature Neuroscience
Verified
Journal Article
Closed access
PPPaola Piccini
Paola Piccini
DBDavid Brooks
David Brooks
ABAnders Björklund
Anders Björklund
RGRoger N. Gunn
Roger N. Gunn
PGPaul M. Grasby
Paul M. Grasby
OLOlle Lindvall
Olle Lindvall

13 June 2006 in Neurology
Verified
Journal Article
Closed access
NPN. Pavese
N. Pavese
AGA. Gerhard
A. Gerhard
YTY. F. Tai
Y. F. Tai
AHA. K. Ho
A. K. Ho
FTFederico Turkheimer
Federico Turkheimer
PPP. Piccini
P. Piccini
Huntington disease (HD) is characterized by the progressive death of medium spiny dopamine receptor bearing striatal GABAergic neurons. In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process. To evaluate in vivo the involvement of microglia activation in HD, the authors studied patients at different stages of the disease using [(11)C](R)-PK11195 PET, a marker of microglia activation, and [(11)C]raclopride PET, a marker of dopamine D2 receptor binding and hence striatal GABAergic cell function. In HD patients, a significant increase in striatal [(11)C](R)-PK11195 binding was observed, which significantly correlated with disease severity as reflected by the striatal reduction in [(11)C]raclopride binding, the Unified Huntington's Disease Rating Scale score, and the patients' CAG index. Also detected were significant increases in microglia activation in cortical regions including prefrontal cortex and anterior cingulate. These [(11)C](R)-PK11195 PET findings show that the level of microglial activation correlates with Huntington disease (HD) severity. They lend support to the view that microglia contribute to the ongoing neuronal degeneration in HD and indicate that [(11)C](R)-PK11195 PET provides a valuable marker when monitoring the efficacy of putative neuroprotecting agents in this relentlessly progressive genetic disorder.

23 March 2006 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
AEAndrew H. Evans
Andrew H. Evans
NPNicola Pavese
Nicola Pavese
ALAndrew D. Lawrence
Andrew D. Lawrence
YTYen F. Tai
Yen F. Tai
SASilke Appel
Silke Appel
PPPaola Piccini
Paola Piccini

30 March 2007 in Brain
Verified
Journal Article
Open access
PDF file
YTYen F. Tai
Yen F. Tai
NPNicola Pavese
Nicola Pavese
AGAlexander Gerhard
Alexander Gerhard
STSarah J. Tabrizi
Sarah J. Tabrizi
RBRoger A. Barker
Roger A. Barker
PPPaola Piccini
Paola Piccini
Microglial activation may play a role in the pathogenesis of Huntington's disease (HD). Using 11C-(R)-PK11195 (PK) positron emission tomography (PET), we investigated microglial activation in HD presymptomatic gene carriers (PGCs), its relationship with striatal neuronal dysfunction measured with 11C-raclopride (RAC) PET, and the role of PK PET as a possible marker of subclinical disease progression in PGCs. Eleven HD PGCs underwent PK and RAC PET. Their results were compared with those of healthy controls. PK and RAC binding was measured using region-of-interest analysis. Regional increases in PK binding were also localized with voxel-based statistical parametric mapping. HD PGCs had lower striatal RAC binding than the controls but significantly higher striatal and cortical PK binding. Individual levels of higher striatal PK binding in PGCs correlated with lower striatal RAC binding and, after excluding one outlier, with a higher probability of developing HD in 5 years. The inverse association between striatal PK and RAC binding in PGCs continues into early to moderate stages of HD. This study demonstrated for the first time in vivo widespread microglial activation in preclinical HD which correlated with striatal neuronal dysfunction. These findings indicate that microglial activation is an early event in the pathogenic processes of HD and is associated with subclinical progression of disease. PK PET may be a useful marker of active subclinical disease and a means of investigating the efficacy of neuroprotection strategies in PGCs.

29 April 2011 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
WMWassilios Meissner
Wassilios Meissner
MFMark Frasier
Mark Frasier
TGThomas Gasser
Thomas Gasser
CGChristopher G. Goetz
Christopher G. Goetz
ALAndres M Lozano
Andres M Lozano
Erwan BezardErwan Bezard
Erwan Bezard